0000950170-23-066386.txt : 20231128
0000950170-23-066386.hdr.sgml : 20231128
20231128160004
ACCESSION NUMBER: 0000950170-23-066386
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230220
FILED AS OF DATE: 20231128
DATE AS OF CHANGE: 20231128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Giffin Brett A.
CENTRAL INDEX KEY: 0001892921
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36571
FILM NUMBER: 231446259
MAIL ADDRESS:
STREET 1: 101 HARTWELL AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: T2 Biosystems, Inc.
CENTRAL INDEX KEY: 0001492674
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 204827488
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-457-1200
MAIL ADDRESS:
STREET 1: 101 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4/A
1
ownership.xml
4/A
X0508
4/A
2023-02-20
2023-03-09
0001492674
T2 Biosystems, Inc.
TTOO
0001892921
Giffin Brett A.
101 HARTWELL AVENUE
LEXINGTON
MA
02421
false
true
false
false
Chief Commercial Officer
false
Common Stock
2023-02-20
4
M
false
1333
A
3586
D
Common Stock
2023-02-20
4
S
false
537
0.65
D
3049
D
Restricted Stock Units
2023-02-20
4
M
false
1333
0
D
Common Stock
1333
2667
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The original Form 4 filed on March 9, 2023 is amended by this Form 4 amendment to correct the amount of securities beneficially owned following the reported transactions.
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on November 10, 2021.
On February 20, 2022 the reporting person was granted 4,000 RSU's that vest in three equal annual installments commencing on February 20, 2023.
/s/ John Sprague, Attorney-in-fact
2023-11-28